Equipe deRecherche ONCOGYMA, University of Mohamed V, Faculty of Medicine and Pharmacy of Rabat Morocco
Abstract
Triple-negative breast cancer (TNBC) is defined as a type of breast carcinoma that is negative for expression of oestrogene and progesterone hormone receptors (ER, PR) and HER2. This form of breast cancer is marked by its aggressiveness, low survival rate and lack of specific therapies. Recently, important molecular characteristics of TNBC have been highlighted and led to the identification of some biomarkers that could be used in diagnosis, as therapeutic targets or to assess the prognosis. In this review, we summarize recent progress in TNBC research focusing on the genetic and epigenetic alterations of TNBC and the potential use of these biomarkers in the targeted therapy for better management of TNBC.
Mouh, F., Mzibri, M., & Amrani, M. (2016). Recent Progress in Triple Negative Breast Cancer Research. Asian Pacific Journal of Cancer Prevention, 17(4), 1595-1608.
MLA
Fatima Zahra Mouh; Mohammed El Mzibri; Mariam Amrani. "Recent Progress in Triple Negative Breast Cancer Research". Asian Pacific Journal of Cancer Prevention, 17, 4, 2016, 1595-1608.
HARVARD
Mouh, F., Mzibri, M., Amrani, M. (2016). 'Recent Progress in Triple Negative Breast Cancer Research', Asian Pacific Journal of Cancer Prevention, 17(4), pp. 1595-1608.
VANCOUVER
Mouh, F., Mzibri, M., Amrani, M. Recent Progress in Triple Negative Breast Cancer Research. Asian Pacific Journal of Cancer Prevention, 2016; 17(4): 1595-1608.
)